Alcoholic hepatitis: from pathogenesis to treatment

References

• Simpson KJ. Pathogenesis of alcoholic hepatic steatosis. Addict Biol 1996;1(4):363–70
   PubMed Web of Science ®Google Scholar
• Edmondson HA, Peters RL, Frankel HH, Borowsky S. The early stage of liver injury in the alcoholic. Medicine (Baltimore) 1967;46(2):119–29
   PubMed Web of Science ®Google Scholar
• Hislop WS, Bouchier IA, Allan JG, et al. Alcoholic liver disease in Scotland and northeastern England: presenting features in 510 patients. Q J Med 1983;52(206):232–43
   PubMedGoogle Scholar
• Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis 1988;8(1):12–25
   PubMed Web of Science ®Google Scholar
• Plee-Gautier E, Foresto F, Ferrara R, et al. Genetic repeat polymorphism in the regulating region of CYP2E1: frequency and relationship with enzymatic activity in alcoholics. Alcohol Clin Exp Res 2001;25(6):800–4
   Google Scholar
• Nagata N, Watanabe N, Tsuda M, Tsukamoto H, Matsuzaki S. Relationship between serum levels of anti-low-density lipoproteinacetaldehyde-adduct antibody and aldehyde dehydrogenase 2 heterozygotes in patients with alcoholic liver injury. Alcohol Clin Exp Res 1999;23\(Suppl 4):24S–28S
   Google Scholar
• Monzoni A, Masutti F, Saccoccio G, Bellentani S, Tiribelli C, Giacca M. Genetic determinants of ethanol-induced liver damage. Mol Med 2001;7(4):255–62
   PubMed Web of Science ®Google Scholar
• Jarvelainen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 2001;33(5):1148–53
   PubMed Web of Science ®Google Scholar
• Iron A, Richard P, Pascual DZ, Dumas F, Cassaigne A, Couzigou P. Genetic polymorphism of apolipoprotein E in Caucasian alcoholic cirrhotics. Alcohol Alcohol 1994;29(6):715–8
   PubMed Web of Science ®Google Scholar
• Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997;26(1):143–6
   PubMed Web of Science ®Google Scholar
• Frenzer A, Butler WJ, Norton ID, et al. Polymorphism in alcohol-metabolizing enzymes, glutathione S-transferases and apolipo-protein E and susceptibility to alcohol-induced cirrhosis and chronic pancreatitis. J Gastroenterol Hepatol 2002;17(2):177–82
   PubMed Web of Science ®Google Scholar
• Brind A, Fryer A, Hurlstone A, Fisher N, Pirmohamed M. The role of polymorphism in manganese superoxide dismutase in susceptibility to alcoholic liver disease. Gastroenterology 2003;124(7):2000–2
   Google Scholar
• Bathgate AJ, Pravica V, Perrey C, Hayes PC, Hutchinson IV. Polymorphisms in tumour necrosis factor alpha, interleukin-10 and transforming growth factor beta1 genes and end-stage liver disease. Eur J Gastroenterol Hepatol 2000;12(12):1329–33
   Google Scholar
• Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37(3):493–503
   Google Scholar
• Agundez JA, Ladero JM, Olivera M, et al. N-acetyltransferase 2 polymorphism is not related to the risk of advanced alcoholic liver disease. Scand J Gastroenterol 2002;37(1):99–103
   PubMed Web of Science ®Google Scholar
• Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol 2000;53(2):88–93
   Google Scholar
• Takamatsu M, Yamauchi M, Maezawa Y, Saito S, Maeyama S, Uchikoshi T. Genetic polymorphisms of interleukin-1beta in association with the development of alcoholic liver disease in Japanese patients. Am J Gastroenterol 2000;95(5):1305–11
   PubMed Web of Science ®Google Scholar
• Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000;46(4):540–5
   Google Scholar
• Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25(1):108–11
   PubMed Web of Science ®Google Scholar
• Iturriaga H, Bunout D, Hirsch S, Ugarte G. Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am J Clin Nutr 1988;47(2):235–8
   PubMed Web of Science ®Google Scholar
• Pianko S, Patella S, Sievert W. Alcohol consumption induces hepatocyte apoptosis in patients with chronic hepatitis C infection. J Gastroenterol Hepatol 2000;15(7):798–805
   Google Scholar
• Pares A, Barrera JM, Caballeria J, et al. Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology 1990;12(6):1295–9
   PubMed Web of Science ®Google Scholar
• Gao B. Interaction of alcohol and hepatitis viral proteins: implication in synergistic effect of alcohol drinking and viral hepatitis on liver injury. Alcohol 2002;27(1):69–72
   PubMed Web of Science ®Google Scholar
• Fletcher LM, Powell LW. Hemochromatosis and alcoholic liver disease. Alcohol 2003;30(2):131–6
   PubMed Web of Science ®Google Scholar
• Baptista A, Bianchi L, de Groote J, et al. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981;1:707–11
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 2001;15(8):1335–49
   PubMed Web of Science ®Google Scholar
• Bjorneboe GE, Johnsen J, Bjorneboe A, et al. Some aspects of antioxidant status in blood from alcoholics. Alcohol Clin Exp Res 1988;12(6):806–10
   PubMed Web of Science ®Google Scholar
• Ziol M, Tepper M, Lohez M, et al. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis. J Hepatol 2001;34(2):254–60
   PubMed Web of Science ®Google Scholar
• Stewart S, Jones D, Day CP. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 2001;7(9):408–13
   Google Scholar
• Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001;34(2):248–53
   PubMed Web of Science ®Google Scholar
• Niemela O, Klajner F, Orrego H, Vidins E, Blendis L, Israel Y. Antibodies against acetaldehyde-modified protein epitopes in human alcoholics. Hepatology 1987;7(6):1210–4
   PubMed Web of Science ®Google Scholar
• Koskinas J, Kenna JG, Bird GL, Alexander GJ, Williams R. Immunoglobulin A antibody to a 200-kilodalton cytosolic acetaldehyde adduct in alcoholic hepatitis. Gastroenterology 1992;103(6):1860–7
   Google Scholar
• Viitala K, Israel Y, Blake JE, Niemela O. Serum IgA, IgG, and IgM antibodies directed against acetaldehyde-derived epitopes: relationship to liver disease severity and alcohol consumption. Hepatology 1997;25(6):1418–24
   PubMed Web of Science ®Google Scholar
• Vidali M, Stewart SF, Rolla R, et al. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003;37(2):410–9
   PubMed Web of Science ®Google Scholar
• Ma Y, Gaken J, McFarlane BM, et al. Alcohol dehydrogenase: a target of humoral autoimmune response in liver disease. Gastroenterology 1997;112(2):483–92
   PubMed Web of Science ®Google Scholar
• Laskin CA, Vidins E, Blendis LM, Soloninka CA. Autoantibodies in alcoholic liver disease. Am J Med 1990;89(2):129–33
   PubMed Web of Science ®Google Scholar
• Chedid A, Chadalawada KR, Morgan TR, et al. Phospholipid antibodies in alcoholic liver disease. Hepatology 1994;20(6): 1465–71
   PubMed Web of Science ®Google Scholar
• Albano E. Free radical mechanisms in immune reactions associated with alcoholic liver disease. Free Radic Biol Med 2002;32(2):110–4
   PubMed Web of Science ®Google Scholar
• Keshavarzian A, Holmes EW, Patel M, Iber F, Fields JZ, Pethkar S. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol 1999;94(1):200–7
   PubMed Web of Science ®Google Scholar
• Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol 1987;4(1):8–14
   Google Scholar
• Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3(9):745–56
   PubMed Web of Science ®Google Scholar
• Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003;66(8):1403–8
   PubMed Web of Science ®Google Scholar
• Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. New Engl J Med 2000;343(20):1467–76
   PubMed Web of Science ®Google Scholar
• Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA 1997;94(4):1441–6
   PubMed Web of Science ®Google Scholar
• Felver ME, Mezey E, McGuire M, et al. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990;14(2):255–9
   PubMed Web of Science ®Google Scholar
• Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112(12):917–20
   Google Scholar
• Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999;117(4):942–52
   PubMed Web of Science ®Google Scholar
• Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997;26(6):1530–7
   Google Scholar
• Heyninck K, Wullaert A, Beyaert R. Nuclear factor-kappa B plays a central role in tumour necrosis factor-mediated liver disease. Biochem Pharmacol 2003;66(8):1409–15
   Google Scholar
• Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119(6):1637–48
   PubMed Web of Science ®Google Scholar
• Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38(4):419–25
   PubMed Web of Science ®Google Scholar
• Kawahara H, Matsuda Y, Takase S. Is apoptosis involved in alcoholic hepatitis? Alcohol Alcohol 1994;29(Suppl 1):113–8
   Google Scholar
• Zhao M, Laissue JA, Zimmermann A. TUNEL-positive hepatocytes in alcoholic liver disease. A retrospective biopsy study using DNA nick end-labelling. Virchows Arch 1997;431(5):337–44
   Google Scholar
• Wyllie AH, Bellamy CO, Bubb VJ, et al. Apoptosis and carcino-genesis. Br J Cancer 1999;80(Suppl 1):34–7
   PubMedGoogle Scholar
• Day CP. Apoptosis in alcoholic hepatitis: a novel therapeutic target? J Hepatol 2001;34(2):330–3
   PubMed Web of Science ®Google Scholar
• Menon KV, Gores GJ, Shah VH. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc 2001;76(10):1021–9
   Google Scholar
• Kwoh-Gain I, Fletcher LM, Price J, Powell LW, Halliday JW. Desialylated transferrin and mitochondrial aspartate amino-transferase compared as laboratory markers of excessive alcohol consumption. Clin Chem 1990;36(6):841–5
   Google Scholar
• Romppanen J, Punnonen K, Anttila P, Jakobsson T, Blake J, Niemela O. Serum sialic acid as a marker of alcohol consumption: effect of liver disease and heavy drinking. Alcohol Clin Exp Res 2002;26(8):1234–8
   PubMed Web of Science ®Google Scholar
• Salaspuro M. Carbohydrate-deficient transferrin as compared to other markers of alcoholism: a systematic review. Alcohol 1999;19(3):261–71
   PubMed Web of Science ®Google Scholar
• Hayes PC. Extrahepatic manifestations of alcoholic liver disease. Baillieres Clin Gastroenterol 1993;7(3):683–96
   PubMedGoogle Scholar
• Diehl AM, Potter J, Boitnott J, Van Duyn MA, Herlong HF, Mezey E. Relationship between pyridoxal 5’-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology 1984;86(4):632–6
   Google Scholar
• Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95(3):734–9
   PubMed Web of Science ®Google Scholar
• Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94(4):1018–22
   Google Scholar
• Maddrey WC, Boitnott JK, Bedine MS, Weber Jr FL, Mezey E, White Jr RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75(2):193–9
   Google Scholar
• Orrego H, Israel Y, Blake JE, Medline A. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 1983;3(6): 896–905
   PubMed Web of Science ®Google Scholar
• Huang YS, Chan CY, Wu JC, Pai CH, Chao Y, Lee SD. Serum levels of interleukin-8 in alcoholic liver disease: relationship with disease stage, biochemical parameters and survival. J Hepatol 1996;24(4):377–84
   PubMed Web of Science ®Google Scholar
• Castera L, Hartmann DJ, Chapel F, et al. Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J Hepatol 2000;32(3):412–8
   PubMed Web of Science ®Google Scholar
• Mundle G, Ackermann K, Munkes J, Steinle D, Mann K. Influence of age, alcohol consumption and abstinence on the sensitivity of carbohydrate-deficient transferrin, gamma-glutamyltransferase and mean corpuscular volume. Alcohol Alcohol 1999;34(5):760–6
   Google Scholar
• Orrego H, Blake JE, Blendis LM, Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987;92(1):208–14
   PubMed Web of Science ®Google Scholar
• Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996;110(6): 1847–53
   PubMed Web of Science ®Google Scholar
• Chapman RW, Morgan MY, Laulicht M, Hoffbrand AV, Sherlock S. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis. Dig Dis Sci 1982;27(10):909–16
   Google Scholar
• Cotler SJ, Bronner MP, Press RD, et al. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J Hepatol 1998;29(2):257–62
   PubMed Web of Science ®Google Scholar
• Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111(6):473–8
   PubMed Web of Science ®Google Scholar
• Morgan MY. The treatment of alcoholic hepatitis. Alcohol Alcohol 1996;31(2):117–34
   PubMed Web of Science ®Google Scholar
• O’Beirne J, Patch D, Holt S, Hamilton M, Burroughs AK. Alcoholic hepatitis – the case for intensive management. Postgrad Med J 2000;76(898):504–7
   Google Scholar
• Schenker S, Halff GA. Nutritional therapy in alcoholic liver disease. Semin Liver Dis 1993;13(2):196–209
   PubMed Web of Science ®Google Scholar
• Carithers Jr RL, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989;110(9):685–90
   PubMed Web of Science ®Google Scholar
• Helman RA, Temko MH, Nye SW, Fallon HJ. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971;74(3):311–21
   Google Scholar
• Lesesne HR, Bozymski EM, Fallon HJ. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978;74(2 Pt 1):169–73
   Google Scholar
• Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New Engl J Med 1992;326(8):507–12
   PubMed Web of Science ®Google Scholar
• Blitzer BL, Mutchnick MG, Joshi PH, Phillips MM, Fessel JM, Conn HO. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977;22(6):477–84
   PubMedGoogle Scholar
• Campra JL, Hamlin Jr EM, Kirshbaum RJ, Olivier M, Redeker AG, Reynolds TB. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med 1973;79(5):625–31
   PubMed Web of Science ®Google Scholar
• Depew W, Boyer T, Omata M, Redeker A, Reynolds T. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980;78(3):524–9
   Google Scholar
• Mendenhall CL, Anderson S, Garcia-Pont P, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. New Engl J Med 1984;311(23):1464–70
   Google Scholar
• Porter HP, Simon FR, Pope CE, Volwiler W, Fenster LF. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. New Engl J Med 1971;284(24):1350–5
   Google Scholar
• Shumaker JB, Resnick RH, Galambos JT, Makopour H, Iber FL. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978;69(4):443–9
   Google Scholar
• Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982;23(1):75–9
   Google Scholar
• Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990;113(4):299–307
   PubMed Web of Science ®Google Scholar
• Mathurin P, Mendenhall CL, Carithers Jr RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36(4):480–7
   PubMed Web of Science ®Google Scholar
• Reynolds TB, Benhamou JP, Blake J, Naccarato R, Orrego H. Treatment of acute alcoholic hepatitis. Gastroenterol Int 1989;(2):208–16
   Google Scholar
• Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995;37(1):113–8
   PubMed Web of Science ®Google Scholar
• McCullough AJ, O’Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998;93(11):2022–36
   PubMed Web of Science ®Google Scholar
• Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003;38(6):1363–9
   PubMed Web of Science ®Google Scholar
• Stewart SF, Day CP. The management of alcoholic liver disease. J Hepatol 2003;38(Suppl 1):S2–S13
   PubMedGoogle Scholar
• Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155(3): 1230–6
   PubMed Web of Science ®Google Scholar
• Morgan TR, McClain CJ. Pentoxifylline and alcoholic hepatitis. Gastroenterology 2000;119(6):1787–91
   PubMed Web of Science ®Google Scholar
• Hill DB, McClain CJ. Anti-TNF therapy in alcoholic hepatitis. Am J Gastroenterol 2004;99(2):261–3
   PubMed Web of Science ®Google Scholar
• Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev 2003;2(6):346–57
   PubMed Web of Science ®Google Scholar
• Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002;37(4): 448–55
   PubMed Web of Science ®Google Scholar
• Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39(5):1390–7
   PubMed Web of Science ®Google Scholar
• Blendis L, Dotan I. Anti-TNF therapy for severe acute alcoholic hepatitis: what went wrong? Gastroenterology 2004;127(5):1637–9
   PubMedGoogle Scholar
• Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151(3): 1548–61
   PubMed Web of Science ®Google Scholar
• Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995;155(10):5038–45
   PubMed Web of Science ®Google Scholar
• Menon KV, Stadheim L, Kamath PS, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004;99(2):255–60
   PubMed Web of Science ®Google Scholar
• McClain CJ. Inhibition of TNF in patients with alcoholic hepatitis, 2004. Reference type: Internet communication
   Google Scholar
• Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis [Veterans Administration Cooperative Study Group on Alcoholic Hepatitis]. Am J Med 1984;76(2):211–22
   Google Scholar
• Mendenhall CL, Tosch T, Weesner RE, et al. VA cooperative study on alcoholic hepatitis. II: prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 1986;43(2): 213–8
   PubMed Web of Science ®Google Scholar
• Schenker S, Halff GA. Nutritional therapy in alcoholic liver disease. Semin Liver Dis 1993;13(2):196–209
   PubMed Web of Science ®Google Scholar
• Stickel F, Hoehn B, Schuppan D, Seitz HK. Review article: nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003;18(4):357–73
   PubMed Web of Science ®Google Scholar
• Mendenhall C, Bongiovanni G, Goldberg S, et al. VA cooperative study on alcoholic hepatitis. III: changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. J Parenter Enteral Nutr 1985;9(5):590–6
   Google Scholar
• Mezey E, Caballeria J, Mitchell MC, Pares A, Herlong HF, Rodes J. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomized controlled trial. Hepatology 1991;14(6):1090–6
   PubMed Web of Science ®Google Scholar
• Simon D, Galambos JT. A randomized controlled study of peripheral parenteral nutrition in moderate and severe alcoholic hepatitis. J Hepatol 1988;7(2):200–7
   PubMed Web of Science ®Google Scholar
• Cabré E, Rodríguez-Iglesias P, Caballería J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000;32(1):36–42
   PubMed Web of Science ®Google Scholar
• Alvarez MA, Cabre E, Lorenzo-Zuniga V, Montoliu S, Planas R, Gassull MA. Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol 2004;16(12):1375–80
   Google Scholar
• Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24(6):1446–51
   PubMed Web of Science ®Google Scholar
• Detry O, Arkadopoulos N, Ting P, et al. Clinical use of a bioartificial liver in the treatment of acetaminophen-induced fulminant hepatic failure. Am Surg 1999;65(10):934–8
   PubMed Web of Science ®Google Scholar
• O’Grady JG, Gimson AE, O’Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94(5 Pt 1):1186–92
   Google Scholar
• Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003;38(1):24–31
   PubMed Web of Science ®Google Scholar
• Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36(4 Pt 1):949–58
   Google Scholar
• Stange J, Mitzner SR, Risler T, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999;23(4):319–30
   PubMed Web of Science ®Google Scholar
• Sorkine P, Ben Abraham R, Szold O, et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001;29(7):1332–6
   PubMed Web of Science ®Google Scholar
• Lucey MR. Is liver transplantation an appropriate treatment for acute alcoholic hepatitis? J Hepatol 2002;36(6):829–31
   PubMed Web of Science ®Google Scholar
• Tome S, Martinez-Rey C, Gonzalez-Quintela A, et al. Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease. J Hepatol 2002;36(6):793–8
   PubMed Web of Science ®Google Scholar
• Neuberger J. Transplantation for alcoholic liver disease: a perspective from Europe. Liver Transpl Surg 1998;4(5 Suppl 1): S51–S57
   Google Scholar
• Conjeevaram HS, Hart J, Lissoos TW, et al. Rapidly progressive liver injury and fatal alcoholic hepatitis occurring after liver transplantation in alcoholic patients. Transplantation 1999;67(12):1562–8
   PubMed Web of Science ®Google Scholar
• Bonet H, Manez R, Kramer D, et al. Liver transplantation for alcoholic liver disease: survival of patients transplanted with alcoholic hepatitis plus cirrhosis as compared with those with cirrhosis alone. Alcohol Clin Exp Res 1993;17(5):1102–6
   PubMed Web of Science ®Google Scholar
• Shakil AO, Pinna A, Demetris J, Lee RG, Fung JJ, Rakela J. Survival and quality of life after liver transplantation for acute alcoholic hepatitis. Liver Transpl Surg 1997;3(3):240–4
   PubMedGoogle Scholar
• Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993;17(4):564–76
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. Am J Gastroenterol 2002;97(7):1674–81
   Google Scholar
• Bucher ML, Swaffield MN. Regulation of hepatic regeneration in rats by synergistic action of insulin and glucagon. Proc Natl Acad Sci USA 1975;72(3):1157–60
   PubMed Web of Science ®Google Scholar
• Feher J, Cornides A, Romany A, et al. A prospective multicenter study of insulin and glucagon infusion therapy in acute alcoholic hepatitis. J Hepatol 1987;5(2):224–31
   PubMed Web of Science ®Google Scholar
• Baker AL, Jaspan JB, Haines NW, Hatfield GE, Krager PS, Schneider JF. A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology 1981;80(6):1410–4
   PubMed Web of Science ®Google Scholar
• Bird G, Lau JY, Koskinas J, Wicks C, Williams R. Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology 1991;14(6):1097–101
   Google Scholar
• Trinchet JC, Balkau B, Poupon RE, et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 1992;15(1):76–81
   PubMed Web of Science ®Google Scholar
• Israel Y, Kalant H, Orrego H, Khanna JM, Videla L, Phillips JM. Experimental alcohol-induced hepatic necrosis: suppression by propylthiouracil. Proc Natl Acad Sci USA 1975;72(3): 1137–41
   PubMed Web of Science ®Google Scholar
• Halle P, Pare P, Kaptein E, Kanel G, Redeker AG, Reynolds TB. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology 1982;82(5 Pt 1):925–31
   Google Scholar
• Orrego H, Kalant H, Israel Y, et al. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology 1979;76(1):105–15
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Gluud C. Meta-analysis of propylthiouracil for alcoholic liver disease – a Cochrane Hepato-Biliary Group Review. Liver 2001;21(6):398–404
   PubMedGoogle Scholar
• Trinchet JC, Beaugrand M, Callard P, et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterol Clin Biol 1989;13(6–7):551–5
   Google Scholar
• Akriviadis EA, Steindel H, Pinto PC, et al. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology 1990;99(3):811–8
   PubMed Web of Science ®Google Scholar
• Madhotra R, Gilmore IT. Recent developments in the treatment of alcoholic hepatitis. Q J Med 2003;96(6):391–400
   Google Scholar
• Maher JJ. Treatment of alcoholic hepatitis. J Gastroenterol Hepatol 2002;17(4):448–55
   PubMed Web of Science ®Google Scholar